Metadata

Identification of each scheme with its given name, when available, or with an identifying label or expression.

High-level description of the defining elements of the scheme, its model of functioning, the stakeholders involved and their role, and other distinguishing features.

Description of the main rationale(s) associated to a given scheme that identifies the intended policy objectives that the stakeholders involved are willing to achieve by using the scheme.

Classification of each scheme as "pricing scheme" or "payment/reimbursement scheme", subject to whether it refers to any approach to price of health technologies from the perspective of the manufacturers, or to any approach to pay for health innovation from the perspective of the payers, respectively.

Classification of each scheme as "theoretical" (i.e., indicating that it has only been proposed or theorized in the literature), or as "applied" (i.e., indicating that it has been implemented and that it is used in real-world contexts).

When applicable, classification of a given scheme as "patient-level" or "population-level", subject to whether the mechanisms that trigger financial or outcome-based aspects of the scheme are defined at the patient- or population-level, respectively.

For schemes that aim at managing at-launch uncertainties around financial or outcome-based dimensions of the scheme, indication of how such risk is shared amongst the parties involved (e.g., manufacturers, payers).

Identification of one or more published sources that illustrate the scheme. Sources could be either scientific publications, or reports from the gray literature.

Example of application of a given scheme in a real-world context, when available. This could be identified by either using the brand name and/or active principle for drugs; the brand name, for medical devices; or other varying labels that identify a given case of application.

Detailed description of the case of application, including its key elements, its functioning, the stakeholders involved, and other distinguishing features.

Indication of the country or countries where the case of application has been implemented.

Indication of the date when the case of application under analysis was first implemented.

Indication of the timeframe of validity of the case of application, namely its duration or the extension over time.

Classification of the case of application based on the type of health technology under analysis, clustering the schemes as being applied to "drugs", "medical devices", "diagnostics", "digital technologies", or combination of these technologies.

When the product category being considered is "drugs", classification of the case of application based on macro-categories of drug types, clustering the schemes as being applied to "patented drugs", "generic drugs", "vaccines", "antibiotics", "ATMPs/gene therapies", or "others".

Indication of the therapeutic area of the health innovation object of the case of application.

Classification of the case of application based on the mode of administration of a given therapy, clustering the schemes as "single-administration" (e.g., for gene therapies), "cycles of treatment" (e.g., for oncologic drugs), or "life-long" (e.g., for chronic diseases).

Identification of the setting of care in which the case of application is delivered, clustering the schemes as "inpatient", "outpatient", or "other".

Indication of the type of healthcare system where the case of application is implemented, typically distinguishing between "tax-based" or "insurance-based" systems.